Amgen, Inc.’s megadeal to acquire Horizon Therapeutics plc and Takeda Pharmaceutical Co. Ltd.’s agreement to purchase a promising investigational drug for psoriasis from Nimbus Therapeutics, Inc. are two recent examples of transactions involving products that can avoid the Medicare price controls established by the Inflation Reduction Act.
The IRA’s impact on the pharma industry’s business model will be profound, but that does not mean drug development or M&A
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?